The recent updates in the investment scene reveal a keen interest in
Edwards Lifesciences Corp (EW). Notably, institutions such as
World Investment Advisors and Swedbank AB hold significant stakes in the company. Other investors have increased their holdings (
California Public Employees Retirement System, OMERS Administration Corp, Bank of Nova Scotia, etc.). Conversely, some entities like
Litman Gregory Wealth Management and Seilern Investment Management have sold off EW shares. Despite a week of decreased market cap, EW's long-term benefits have been positive for institutional investors. Amid this, the
FDA has approved EW's groundbreaking
SAPIEN M3 Mitral Valve Replacement System. Further, the company's shares have been reassessed for valuation after
JP Morgan’s upgrade and its performance spotlight at the 2026 Conference. Renewed interest has been noted after the company's updated Entering 2025 Earnings Guidance. The company's shares receive a moderate buy recommendation from analysts. Recent assessments suggest Edwards Lifesciences is outperforming the healthcare sector, and the company's robust
TAVR growth is expected to drive its Q3 earnings. Despite a move by FTC to block Edwards Lifesciences' acquisition of JenaValve, the company remains a strong and steady entity in the healthcare sector.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 27 Dec 2025 14:01:03 GMT -
Rating +5
- Innovation +4
- Information +6
- Rumor +3
